Rankings
▼
Calendar
KNSA Q2 2018 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q2 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$22M
Net Income
-$20M
EPS (Diluted)
$-1.11
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$18M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$365M
Total Liabilities
$23M
Stockholders' Equity
$342M
Cash & Equivalents
$286M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$22M
-$11M
-89.0%
Net Income
-$20M
-$11M
-80.8%
← FY 2018
All Quarters
Q3 2018 →